Pulse Journal Club Trending Explore Questions Researchers

Download the App

Join discussions, follow papers, and never miss your next session.

© Synapse Social LLC, 2026Privacy Policy

Home Explore Journal Club Trending

⌘+K

Evaluating serum free light chain ratio as a biomarker in multiple myeloma | Synapse

October 3, 2024Open Access

Evaluating serum free light chain ratio as a biomarker in multiple myeloma

Key Points

Key points are not available for this paper at this time.

Abstract

Not available.

Read Full Paperexternally

Mark Helpful

Bookmark

Relay

View Full Paper

Mark Helpful

Bookmark

Relay

View Full Paper

Cite This Study

Akhlaghi et al. (Thu,) studied this question.

synapsesocial.com/papers/68e55ee7e2b3180350efbd26 https://doi.org/https://doi.org/10.3324/haematol.2024.285531

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Serum free light chain concentration and ratio‐based criterion for myeloma‐defining event, in its current version, is untenable2026 · 1 citations
2Molar Ratio of Free Light Chain to Monoclonal Protein as a Potential Prognostic Marker in Intact Immunoglobulin Multiple Myeloma2026
3Predictive Value of Free Light Chain Ratio and Urinary M-Protein for Renal Involvement and Disease Progression in Multiple Myeloma2025
4The role of minimal residual disease and serum free light chain ratio in the management of multiple myeloma2024 · 1 citations
5Comparative analysis of three different serum-free light chain assays in the diagnosis of multiple myeloma2026